Breakthrough Chikungunya Vaccine of Valneva’s: Phase 3 trial Data
Valneva, a renowned global market leader in vaccine development, has published the research clinical data of its Chikungunya Vaccine candidate Phase 3, VLA1553. The groundbreaking results of VLA1553 can be found in the prestigious medical journal, The Lancet. With Chikungunya…
Enhancing Brain Cancer Treatment: Biodegradable Ultrasound Holds Promise
In the realm of brain cancer treatment, one of the major challenges lies in effectively delivering chemotherapy drugs through the tightly coiled blood vessels of the brain. However, a groundbreaking development in the form of a biodegradable ultrasound device could…
Blood test can now diagnose Glut1 deficiency syndrome
Glut1 deficiency syndrome is a rare and disabling neurological disease still relatively unknown to the medical community. A mutation in the SLC2A1 gene in affected patients causes the glucose transporter GLUT1 to malfunction. Since this transporter is responsible for the…
